GLP-1 and glucagon drugs
Drugs that act on two receptors, GLP-1 and glucagon, a hormone that raises blood sugar.
In this group
- MazdutideA weekly shot acting on GLP-1 and glucagon, approved in China.Approved in China in 2025, for weight management and for type 2 diabetes; not approved by the FDA.
- SurvodutideA weekly shot acting on glucagon and GLP-1, tested for weight and for fatty liver disease.Not approved by the FDA, and in phase 3 trials as of October 2026.
- PemvidutideA GLP-1 and glucagon shot, now in trials for liver disease and alcohol use disorder.Not approved by the FDA, and in a phase 3 trial for MASH as of October 2026.
Related: The GLP-1 family
Get an early invite to Tidepath
The app isn't in the App Store yet. Leave your email for an early invite, and tips for your first month.
Get an early invite, tips and occasional news from Tidepath. Unsubscribe anytime. Privacy · Health data privacy · Sender and contact details